Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
- 1 February 1993
- Vol. 71 (S3), 1098-1109
- https://doi.org/10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g
Abstract
Advanced adenocarcinoma of the prostate after hormonal manipulation has been noted to be a relatively chemotherapeutic nonresponsive tumor. Earlier reviews have reported objective responses, that is, complete and partial remissions in 6.5% of 3184 patients, and the current review examines the efficacy of new agents. The current review consists of 26 new drug trials culled from papers and abstracts published between 1987-1991. Results of these 26 drug trials found a similar trend, 8.7% (95% confidence interval, 6.4-9.0%), indicating that hormone-resistant adenocarcinoma of the prostate still fails to respond to most cytotoxic agents. The most interesting of the new therapeutic agents is the combination of vinblastine plus estramustine. Only six agents had an objective response rate greater than 10%, such as vinblastine by continuous infusion, trimetrexate, mitoguazone, and estramustine. The recent introduction of radioactive-labeled monoclonal antibodies is intriguing and these will undoubtably be used as carriers for radiotherapeutic and cytotoxic compounds. Although multidrug resistance may explain the marginal efficacy of cytotoxic drugs, methods to overcome such resistance and, more importantly, new classes of agents must be developed. In addition, reliable disease markers must be found for osseous and visceral metastases to avoid the prevailing confusion in evaluating more precisely the destruction of prostate cancer cells.Keywords
This publication has 28 references indexed in Scilit:
- Cancer statistics, 1991CA: A Cancer Journal for Clinicians, 1991
- Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)The Prostate, 1991
- Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cellsCancer Letters, 1990
- Treatment of hormone‐refractory stage D carcinoma of prostate with coumarin (1,2‐benzopyrone) and cimetidine: A pilot studyThe Prostate, 1990
- Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.The Journal of cell biology, 1988
- Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide National prostatic cancer project randomized trialUrology, 1988
- Phase I trial of α-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancerUrology, 1986
- Interferon‐β treatment of metastatic prostate cancerJournal of Surgical Oncology, 1986
- A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinomaCancer, 1985
- Cytotoxic properties of estramustine unrelated to alkylating and steroid constituentsUrology, 1984